The authors review drug biotransformation. Phase I reactions are preconjugation processes that take place through cytochrome P-450—a hepatic mixed function oxidase (MFO) enzyme system with multiple isozymes to metabolize foreign substances. Phase II reactions are conjugation processes of the substrates. Based on the characteristics of the cytochrome P-450 microsomal enzyme systems, the authors explain the clinical phenomena of induction and inhibition of these enzymes when psychotropic agents interact. This article describes both MFO inducers (barbiturates) and inhibitors (cimeditine, fluoxetine and neuroleptic drugs). With this information, clinicians can enhance the ability to monitor drug interactions of psychotropic agents.
BlackwellB.SchmidtG. L., Drug Interactions in Psychopharmacology, Psychiatric Clinics of North America, 7, pp. 625–637, 1984.
2.
WarnesH.LehmannH. E., Adynamic Ileus during Psychoactive Medication: A Review of Three Fetal and Five Severe Cases, Canadian Medical Association Journal, 96, pp. 1112–1113, 1967.
3.
AranaG. W.GoffD. C.FriedmanH.OrnsteenM.GreenblattD. J.BlackB.ShaderR. I., Does Carbamazepine-Induced Reduction of Plasma Haloperidol Levels Worsen Psychotic Symptoms?, American Journal of Psychiatry, 143, pp. 650–651, 1986.
4.
ShaderR. I.CirauloD. A.GreenblattD. I., Drug Interactions Involving Psychotropic Drugs, Psychosomatics, 19, pp. 671–681, 1978.
5.
SargentiC. J.RizosA. L.JesteD. V., Psychotropic Drug Interactions in the Patient with Late-Onset Psychosis and Mood Disorder: Part I, Psychiatric Clinics of North America, 11, pp. 235–252, 1988.
6.
RizosA. L.SargentiC. J.JesteD. V., Psychotropic Drug Interactions in the Patient with Late-Onset Depression or Psychosis: Part II, Psychiatric Clinics of North America, 11, pp. 253–277, 1988.
7.
CirauloD. A.ShaderR. I.GreenblattD. J.CreelmanW., (eds.), Drug Interactions in Psychiatry, Williams and Wilkins, Baltimore, 1989.
8.
PerryP. J.AlexanderB.LiskowB. I., Psychotropic Drug Handbook, (4th Edition), Harvey Whitney Books, Cincinnati, 1981.
9.
WeibertR. T.NorcrossW. A., (eds.), Drug Interactions Index, (2nd Edition), Medical Economics Books, Oradell, New Jersey, 1988.
10.
LaderM., Introduction to Psychopharmacology, Upjohn, Kalamazoo, Michigan, 1980.
11.
DahlS. G., Plasma Level Monitoring of Antipsychotic Drugs Clinical Utility, Clinical Pharmacokinetics, 11, pp. 36–61, 1986.
12.
RudorferM. V.PotterW. Z., Chapter 142: Pharmacokinetics of Antidepressants, in Psychopharmacology: Third Generation of Progress, MeltzerH. Y. (ed.), Raven Press, New York, pp. 1353–1363, 1987.
13.
FroemmingJ. S.LamY. W. F.JannM. W.DavisC. M., Pharmacokinetics of Haloperidol, Clinical Pharmacokinetics, 17, pp. 396–423, 1989.
14.
BenetL. Z.MitchellJ. R.SheinerL. B., Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, and Elimination, in The Pharmacological Basis of Therapeutics, (8th Edition), GilmanA. G.RailT. W.NiesA. S.TaylorP. (eds.), Pergamon Press, New York, pp. 3–32, 1990.
15.
CorreiaM. A.CastagnoliN.Jr., Pharmacokinetics: II. Drug Biotransformation, in Basic and Clinical Pharmacology, 4th edition, KatzungB. G. (ed.), Appleton and Lange, Norwalk, Connecticut/San Mateo, California, pp. 41–50, 1988.
16.
ZoharJ.ShlaffmanP.BelmakerR. H., The Effect of Amobarbital Sleep Medication on Plasma Levels of Neuroleptics, Human Psychopharmacology and Clinical Experiments, in press.
17.
Van der GraeffM.VermeullenN. P. E.LangendijkN. P. J.BreimerD. D., Pharmacokinetics of Simultaneously Administered Hexobarbital and Heptobarbital in Rats: An Alternative Approach to Metabolic Correlation Studies, Journal of Pharmacology and Experimental Therapeutics, 225, pp. 747–751, 1983.
18.
BallingerB. R.PresleyA.ReidA. H.StevensonI. H., The Effect of Hypnotics on Imipramine Treatment, Psychopharmacolgia, 39, pp. 367–374, 1984.
19.
ForrestF. M.ForrestI. S.SerraM. I., Modification of Chlorpromazine Metabolism by Some Other Drugs Frequently Administered to Psychiatric Patients, Biological Psychiatry, 2, pp. 53–58, 1970.
20.
LogaS.CurryS.LaderM., Interactions of Orphenadrine and Phenobarbitone with Chlorpromazine: Plasma Concentrations and Effects in Man, British Journal of Clinical Pharmacology, 2, pp. 197–208, 1975.
21.
EichelbaumM.EkbomK.BertilssonL.RingsbergerV. A.RaneA., Plasma Kinetics of Carbamazepine and Its Epoxide Metabolism in Man after Single and Multiple Doses, European Journal of Clinical Pharmacology, 8, pp. 337–341, 1975.
22.
FaigleJ. M.BrechbuhlerS.FeldmanK. F.RichterW. J., The Biotransformation of Carbamazepine, in Epileptic Seizures-Behavior-Pain, BirkmayerB. (ed.), Hans Huber, Berne, Switzerland, pp. 127–140, 1976.
23.
KidronR.AverbuchI.DleinE.BelmakerR. H., Carbamazepine-Induced Reduction of Blood Levels of Haloperidol in Chronic Schizophrenia, Biological Psychiatry, 20, pp. 199–228, 1985.
24.
CurryS. H.DavisJ. M.JanowskyD. S.MarshallJ. H., Factors Affecting Chlorpromazine Plasma Levels in Psychiatric Patients, Archives of General Psychiatry, 22, pp. 209–215, 1970.
25.
SedvallG., Antipsychotics: Pharmacodynamics and Clinical Pharmacokinetics, in Clinical Pharmacology in Psychiatry, UsdinE.DavidJ. M.GlassmanA. H.GreenblattD. J.PerelJ. M.ShaderR. I. (eds.), Elsevier, New York, pp. 243–249, 1981.
26.
StevensonI. H.SchiffA. A., The Effect of Fluphenazine on Steady-State Plasma Levels of Nortriptyline, British Journal of Clinical Pharmacology, 1, pp. 337–338, 1974.
27.
GramL. F.PedersenO. L.KristensenC. B.BjerreM.Kragh-SrensenP., Drug Level Monitoring in Psychopharmacology: Usefulness and Clinical Problems with Special Reference to Tricyclic Antidepressants, Drug Monitoring, 4, pp. 17–25, 1982.
28.
SerlinM. J.SibeonR. B.MossmanS.BreckenridgeA. M.WilliamsJ. R. B.AltwoodJ. L.WilloughbyJ. M. T., Interaction with Oral Anticoagulants in Man, The Lancet, 2, pp. 317–319, 1979.
29.
DesmondP. V.PatwardhanR. V.ShenkerS.SpeegK. V.Jr., Cimetidine Impairs the Elimination of Chlordiazepoxide (Librium) in Humans, Annals of Internal Medicine, 93, pp. 266–268, 1980.
30.
KlotzU.AnttilaV-JReimannI., Cimetidine/Diazepam Interaction (letter), The Lancet, 2, p. 699, 1979.
31.
GreenblattD. J.AbernathyD. R.MorseD. S.HarmatzJ. S.ShaderR. I., Clinical Importance of the Interaction of Diazepam and Cimetidine, New England Journal of Medicine, 318, pp. 1639–1643, 1984.
32.
SpinaE.KoikeY., Differential Effects of Cimetidine and Ranitidine on Imipramine Demethylation and Desmethylimipramine Hydroxylation by Human Liver Microsomes, European Journal of Clinical Pharmacology, 30, pp. 239–242, 1986.
33.
PatwardhanR. V.YarboroughG. W.DesmondP. V.JohnsonR. F.SchenkerS.SpeegK. V.Jr., Cimetidine Spares the Glucuronidation of Lorazepam and Oxazepam, Gastroenterology, 79, pp. 912–916, 1980.
34.
RailT. W., Hypnotics and Sedatives; Ethanol, in The Pharmacological Basis of Therapeutics, (8th Edition), GilmanA. G.RailT. W.NiesA. S.TaylorP. (eds.), Pergamon Press, New York, pp. 345–382, 1990.
35.
GiarmanN. J.FlickF. H.WhiteJ. M., Prolongation of Thiopental Anesthesia in the Mouse by Premedication with Tetraethylthiuram (“Antabuse”), Science, 114, pp. 35–36, 1951.
36.
AranowR. B.HudsonJ. I.PopeH. G.Jr.GradyT. A.LaageT. A.BellI. R.ColeJ. O., Elevated Antidepressant Plasma Levels after Addition of Fluoxetine, American Journal of Psychiatry, 146, pp. 911–913, 1989.
37.
DownsJ. M.DownsA. D.RosenthalT. L.DealN.AkiskalH. S., Increased Plasma Tricyclic Antidepressant Concentrations in Two Patients Concurrently Treated with Fluoxetine, Journal of Clinical Psychiatry, 50, pp. 226–227, 1989.
38.
VaughanD. A., Interaction of Fluoxetine with Tricyclic Antidepressants, American Journal of Psychiatry, 145, p. 1478, 1988.
39.
GoodnickP. J., Influence of Fluoxetine on Plasma Levels of Desipramine, American Journal of Psychiatry, 146, p. 552, 1989.
40.
TateJ. L., Extrapyramidal Symptoms in a Patient Taking Haloperidol and Fluoxetine (letter), American Journal of Psychiatry, 146 pp. 399–400,1989.
41.
BouchardR. H.PourcherE.VincentP., Fluoxetine and Extrapyramidal Side Effects (letter), American Journal of Psychiatry, 146, pp. 1352–1353,1989.
42.
BondT. M., Fluoxetine and Extrapyramidal Side Effects (letter), American Journal of Psychiatry, 146, p. 1353, 1989.
43.
LembergerL.RoweH.BosomworthJ. C.TenbargeJ. B.BergstromR. F., The Effect of Fluoxetine on the Pharmacokinetics and Psychomotor Responses of Diazepam, Clinical Pharmacology and Therapeutics, 43, pp. 412–419, 1988.
44.
VandelB.VandelS.AllersG.BechtelP.VolmatR., Interaction between Amitriptyline and Phenothiazine in Man: Effect on Plasma Concentration of Amitriptyline and Its Metabolite Nortriptyline and Correlation with Clinical Response, Psychopharmacology, 65, pp. 187–190,1979.
45.
MoodyJ. P.TaitA. C.TodrickA., Plasma Levels of Imipramine and Desmethylimipramine During Therapy, British Journal of Psychiatry, 113, pp. 183–193, 1967.
46.
GramL. F.OverøK. F., Drug Interaction: Inhibitory Effect of Neuroleptics on Metabolism of Tricyclic Antidepressants in Men, British Medical Journal, 1, pp. 463–465, 1972.
47.
GramL. F.OverøK. F.KirkL., Influence of Neuroleptics and Benzodiazepines on Metabolism of Tricyclic Antidepressants in Man, American Journal of Psychiatry, 131, pp. 863–866, 1974.
48.
NelsonJ. C.JatlawP. I., Neuroleptic Effect on Desipramine Steady-State Plasma Concentrations, American Journal of Psychiatry, 137, pp. 1232–1234, 1980.
49.
Olivier-MartinR.MarzinD.BuschsenschutzE.PichotP.BoissierJ., Concentration Plasmatiques de L'imipramine et de la Demethylimipramine et Effect Anti-depresseur au cours d'un Traitement Controle, Psychopharmacology, 41, pp. 187–195, 1975.
50.
BrøsenK.GramL. F.KlysnerR.BechP., Steady-State Levels of Imipramine and Its Metabolites: Significance of Dose-Dependent Kinetics, European Journal of Clinical Pharmacology, 30, pp. 43–49, 1986.
51.
GramL. F., Effects of Perphenazine on Imipramine Metabolism in Man, Psycho-pharmacology Communication, 1, pp. 165–175, 1975.
52.
GramL.F.ChristansenJ.OverøF., Pharmacokinetic Interaction between Neuroleptics and Tricyclic Antidepressants in Rat, Acta Pharmacologica et Toxicologica, 35, pp. 223–232, 1974.
